Telomere Recapping Prevents Pathogenic Telomere-To-Mitochondrial DNA Communication In Heart Failure
Heart failure remains a significant health challenge, with current treatments offering limited long-term success. A recent breakthrough sheds light on a previously unrecognized mechanism contributing to this condition and proposes an innovative therapeutic strategy.
Our cells contain structures called chromosomes, which carry our genetic information. At the very ends of these chromosomes are protective caps known as telomeres. In individuals with heart failure, the muscle cells of the heart, called cardiomyocytes, often have shortened telomeres. This shortening acts like a distress signal, triggering a “DNA damage response” within the cell. This response, in turn, negatively impacts the mitochondria, which are the vital powerhouses of our cells responsible for generating energy.
The research uncovered a specific pathway: when telomeres become unprotected, they activate a protein called p53. This activated p53 then interferes with the normal functioning of mitochondria, specifically hindering the creation of new mitochondria (a process called mitochondrial biogenesis) and causing detrimental modifications to the mitochondrial DNA. This entire chain of events—from unprotected telomeres to p53 activation and subsequent mitochondrial dysfunction—appears to be a major driver of heart failure.
To counteract this, scientists developed a novel gene therapy. They engineered a modified protein (JV101) designed to “recap” or re-protect the telomere ends without actually lengthening them. This modified protein was delivered to heart cells using a harmless virus. The results were promising: this “telomere recapping” treatment successfully quieted the p53 protein, restored the production of new mitochondria, and prevented the harmful changes to mitochondrial DNA. Crucially, it also improved heart function in various experimental models of heart failure, including in human heart cells grown in the lab.
This discovery highlights the critical role of communication between telomeres and mitochondrial DNA in the progression of heart failure. It also provides a compelling proof-of-concept for a new gene therapy approach that targets telomeres to potentially restore heart function and improve outcomes for patients with heart failure.
Source: link to paper